Navigation Links
Biohaven Files Registration Statement for Proposed Public Offering of its Common Shares
Date:4/8/2017

TORONTO, April 7, 2017 /PRNewswire/- Portage Biotech Inc. ("Portage") (OTC: PTGEF, Canadian Securities Exchange: PBT.U) announced today that Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven"), in which Portage holds an equity interest of approximately 28.3%, issued a press release today announcing that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed offering of its common shares.

A copy of the preliminary prospectus, when available, may be obtained by mail from the offices of Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at (800) 747-3924, or by email at prospectus@pjc.com; or from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (888) 603-5847, e-mail: Barclaysprospectus@broadridge.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About Biohaven

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has licensed intellectual property from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital.  Biohaven is a company organized under the laws of the British Virgin Islands and its United States operations are based in New Haven, Connecticut.

About Portage

Portage is engaged in the discovery and development of pharmaceutical and biotech products through clinical "proof of concept" with a focus on areas of unmet clinical need. Following proof of concept, Portage will seek to sell or license these products to large pharmaceutical or biotechnology companies for further development and commercialization. Portage has an interest in novel targeted therapies, stem cell therapies, and new indications for older marketed products that have been found to have novel patentable characteristics that bring new value to patients.

Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.  Any such statements reflect Portage's current views and assumptions about future events and financial performance.  Portage cannot assure that future events or performance will occur. Important risks and factors that could cause actual results or events to differ materially from those indicated in our forward-looking statements.

Portage assumes no obligation and expressly disclaims any duty to update the information in this News Release.


'/>"/>
SOURCE Portage Biotech Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Portages Biohaven enters into exclusive formulation agreement and global license with Catalent for lead product
2. Portages Biohaven Announces Agreement with inVentiv Health
3. Portages Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016
4. Portages Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing
5. Portages Biohaven Acquires Intellectual Property for Portfolio of Prodrugs from ALS Biopharma, LLC
6. Portages Biohavens lead drug candidate clears FDA Investigational New Drug Application (IND) review and clinical studies to begin
7. Portages Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223
8. Biohaven and Fox Chase Chemical Diversity Center Announce Strategic Alliance in Early Stage Drug Discovery Research
9. Portages Biohaven Completes Multiple Dose Phase of Pharmacokinetic Trial with BHV-0223
10. Portages Biohaven announces Phase 1 pharmacokinetic study meets study objectives and supports advancing BHV-0223 and also appoints a CEO
11. Biohaven Announces Phase 1 Pharmacokinetic Study Meets Study Objectives and Supports Advancing BHV-0223
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2019)... , ... September 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... Science & Technology will present at the upcoming Nordic Life Science Days ...
(Date:8/27/2019)... ... 27, 2019 , ... Dr. Kim Carlson is a veterinary surgeon practicing in ... Surgical Group , a new surgical practice in San Mateo. She is currently ... more veterinary specialists as the practice grows. , When asked about the opening of ...
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... Scientific Advisory Board. Mr. Lawrence is a member of the Institute of Food ... Safety and Health (IFSH) Advisory Board, Joint Institute for Food Safety and Applied ...
(Date:8/6/2019)... ... August 06, 2019 , ... The San Diego Biotechnology ... the biweekly SDBN BUZZ podcast focused on connecting the region’s biotech community and ... to promote the region and attract external employers, investors, scientists, and others who ...
Breaking Biology Technology:
(Date:8/29/2019)... ... , ... Lajollacooks4u has expanded its team as it gears up for a ... seen record growth in 2019, having hosted a multitude of team-building events and cooking ... visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard to accommodate the ...
(Date:8/27/2019)... Fla. (PRWEB) , ... August 27, 2019 , ... ... in life science and drug development. This episode is scheduled to broadcast 4Q/2019. ... explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show will ...
(Date:8/21/2019)... ... August 20, 2019 , ... Cutting Edge ... for the spine, today announced the 510(K) clearance of its novel SI joint ... is proven to improve osseointegration through superior hydrophilicity and optimized surface chemistry, as ...
Breaking Biology News(10 mins):